Filter by:
Topic
Resource Type
Display Only
Showing 112 Results
Comments to FTC on Business Practices of PBMs and Their Impact on Pharmacies and Consumers
NPC submitted comments to the Federal Trade Commission encouraging the study of anti-competitive business practices of pharmacy benefit managers and their impact on drug affordability and access.
E.V.I.dently® | March 2022
In this issue: Measuring the impact of innovation, new resources to navigate health spending research and policy-making, good practices for HDHPs and a busy spring event calendar.
E.V.I.dently® | January 2022
In this issue: We offer a new resource on the myth of the "average" patient, outline key challenges in value assessment and health technology assessment, and highlight two upcoming webinars.
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2023
NPC offers research-based comments to improve patient access to care and health equity.
E.V.I.dently® | November 2021
In this issue: Explore the pitfalls in the most recent drug pricing deal, regulation that's led to improvements in employee benefits and keys to improving equity in health coverage.
E.V.I.dently® | September 2021
In this issue: Explore drug pricing and innovation, patient input in health benefit design, the research infrastructure to examine social determinants of health and upcoming events.
NPC Comments on CMS' Proposed Medicare Shared Savings and Physician Fee Policies
NPC offers research-based comments to improve CMS' Merit-based Incentive Payment System Value Pathways and quality measurement.
E.V.I.dently® - July 2021
In this issue: meet NPC's new president and CEO, learn how we can tackle low-value care, what we need to know about the budget cap dilemma, and catch up on news you might have missed!
NPC Reiterates Comments on Medicare Program; Medicare Coverage of Innovative Technology, Definition of “Reasonable and Necessary”
NPC resubmitted comments on a proposed rule to establish a Medicare coverage pathway for medical devices designated as breakthrough by the FDA.
NPC Comments on Most Favored Nation (MFN) Model [CMS-5528-IFC]
NPC explains how using payment models based on pricing in other countries could have a negative impact on patient outcomes, access to treatments and future innovation.
NPC Comments on PCORI's Proposed Principles for the Consideration of the Full Range of Outcomes Data
NPC offered public feedback to PCORI on its new mandate to consider the full range of patient-centered outcomes in its research.
NPC Comments on Medicare Program; Medicare Coverage of Innovative Technology, Definition of “Reasonable and Necessary”
NPC submitted comments on a proposed rule to establish a Medicare coverage pathway for medical devices designated as breakthrough by the FDA.
E.V.I.dently October 2020
This month marks the last time you’ll see E.V.I.dently® in its current format and layout. That’s because we’re working on some exciting changes to our e-newsletters and website, with an eye toward…
NPC Comments on CMS Proposed Rule on Medicaid Best Price, Value-based Purchasing
NPC outlines barriers and potential solutions to the broader use of value-based purchasing agreements.